2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 343-345
Treatment Considerations, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, B Cell Lymphoma, Research, AML, Clinical Research, Clinical Trials, Study Population, Human, Pediatric, Young Adult
PAPER

562 A Phase II study of donor-derived IL-21 expanded natural killer (NK) cell infusions in children and young adults (CAYA) with high-risk acute myeloid leukemia (AML) receiving myeloablative human leukocyte antigen-haploidentical hematopoietic cell transplantation (haploHCT): A multicenter pediatric transplantation and cellular therapy Consortium (PTCTC) study (EXCEL Trial)

Hemalatha Geetharani Rangarajan I, MD, Challice Bonifant, MD, PhD2, Michael Verneris, MD3, Mitchell Cairo, MD4, Aliza Gardenswartz, MD5, Toshihiro Onishi, MD6, Jodi Skiles, MD7, Sonali Chaudhury, MD8, Roberta H Adams, MD9, Brian P Tullius, MD10, Rachel Phelan, MD, MPH11, Rabi Hanna, MD12, Jemily Malvar13, Yueh-Yun Chi, PhD14, Prithy Martis15, Lawrence Gazda, MD16, Margaret Lamb, MD17, Scott N Furlan, MD18, Elizabeth Gourdine, MD19, Karely Van Thiel Berghuijs, MS20, Michelle Watts21, Michael A. Pulsipher, MD22, Dean A Lee, MD.PhD23, Monica Thakar, MD24
1 Nationwide Children's Hospital, Columbus, Ohio, United States
2 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
3 Children’s Hospital Colorado and CU Anschutz, Denver, Colorado, United States
4 Maria Fareri Children’s Hospital, New York Medical College, Westchester, New York, United States
5 Maria Fareri Children’s Hospital, New York Medical College, Westchester, New York, United States
6 Phoenix Children’s Hospital and Mayo Clinic Arizona, Phoenix, Arizona, United States
7 Riley Children’s Hospital, Indiana University School of Medicine, Indianapolis, Indiana, United States
8 Lurie Children's hospital, Northwestern University, Chicago, Illinois, United States
9 Phoenix Children’s Hospital and Mayo Clinic Arizona, Phoenix, Arizona, United States
10 AdventHealth for Children, Orlando, Florida, United States
11 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
12 Cleveland Clinic Children’s, Cleveland, United States
13 Cancer and Blood Disease Institute, Children’s Hospital Los Angeles, Los Angeles, California, United States
14 Cancer and Blood Disease Institute, Children’s Hospital Los Angeles, Los Angeles, California, United States, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, United States
15 Abigail Wexner Research Institute of Nationwide Children’s Hospital, Columbus, Ohio, United States
16 Abigail Wexner Research Institute of Nationwide Children’s Hospital, Columbus, Ohio, United States
17 Nationwide Children's Hospital, Columbus, Ohio, United States
18 Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States, Department of Pediatrics, University of Washington, Seattle, Washington, United States
19 Cancer and Blood Disease Institute, Children’s Hospital Los Angeles, Los Angeles, California, United States
20 Intermountain Primary Children’s Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Utah, Utah, United States
21 Nationwide Children's Hospital, Columbus, Ohio, United States
22 Intermountain Primary Children’s Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Utah, Utah, United States
23 Nationwide Children's Hospital, Columbus, Ohio, United States
24 Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States, Department of Pediatrics, University of Washington, Seattle, Washington, United States

Background: Relapse is the leading cause of treatment failure and mortality after allogeneic HCT for AML. Unfortunately, salvage remains largely unsuccessful, highlighting the critical need for effective strategies to prevent relapse. While the anti-AML activity of NK cells is well-described in HCT, NK cell reconstitution is markedly delayed in haploHCT with post-HCT cyclophosphamide (PTCy). To overcome this limitation, we initiated a clinical trial delivering expanded donor-derived NK cells (haploNK) into CAYA AML participants (pts) undergoing haploHCT, previously tested in adults undergoing reduced-intensity HCT (Ciurea, Leukemia, 2022).

Methods: Pts <25 years of age with AML in remission (< 5% blasts) and adequate organ function were eligible for enrollment. Building on predecessor PTCTC Study NCT02120157 (Fierro-Pineda, Blood Adv 2023), pts were conditioned using myeloablative busulfan (AUC: 65-75 mg.h/L) and cyclophosphamide (BuCy). Graft-versus-host disease (GVHD) prophylaxis consisted of PTCy, tacrolimus, and mycophenolate mofetil. Donor whole blood (≤450 mL) was collected at the treating center 3 weeks before recipient conditioning and shipped fresh to the central academic manufacturing facility. HaploNK were expanded ex vivo for 14 days in Xuri bioreactors using K562 feeder cells expressing membrane-bound IL-21 and 4-1BB ligand. Three pt-specific cryopreserved haploNK (1e8/kg per dose) were returned to treating centers and infused on days (D)−1, D7, and D42 to 90 peri-HCT. Pts were evaluable if they received at least the D7 NK infusion. The Kaplan-Meier method was used to estimate relapse-free survival (RFS), event-free survival (EFS), and overall survival (OS); cumulative incidence of non-relapsed mortality (NRM) and relapse (RI) were estimated in the context of competing risks.

Objectives: Primary objective was to estimate 1-year RFS. Secondary objectives were to evaluate the feasibility of manufacturing/distribution and safety of approach, and to estimate 1-year OS, EFS, NRM, and RI. Correlative studies evaluated patterns of immune reconstitution and their impact on RI and OS using longitudinal flow cytometry and single cell sequencing.

Results: Thirty pts with median age 8 (0.5-23) years at HCT were enrolled from Nov 2021-Dec 2025. Pts had mostly high-risk disease; 73% had adverse risk by 2022 European Leukemia Network (ELN22) criteria. By clinical remission (CR) status, 77% were in CR1, 23% in ≥CR2. All but one was MRD neg (<0.01% by flow) pre-HCT. On-demand manufacturing of haploNK was successful for all pts, yielding products with high NK purity (median 96%, range 80-99%), negligible T-cell content (median 0.01%, range 0-0.26%), robust expansion (median 2,755-fold, range 274-22,980) and a median of 9 (range 2-62) doses per pt. Administration of repeated haploNK was feasible and well-tolerated, with limited cytokine release syndrome (n=1). EBMT-defined severe/very severe veno-occlusive disease occurred in 30% and fully resolved. None experienced NRM by D100. Four patients developed CTCAE v5 grade 4-5 infections, all of which were bacterial. Three pts developed graft failure and are alive/well after boost (n=1) or died of relapse (n=1) or late NRM (n=1). Incidence of D100 severe acute GVHD was low (grades 3-4=7%). All relapses occurred within the first 7 months (median 111 (28-223) days) after HCT. The estimated 1-year RFS (95% CI) was 52 (32-68)%, OS 75 (54-87)%, and EFS 48 (29-65)%, while 1-year cumulative incidence NRM was 10 (3-25)% and RI 38 (20-55)%. Pts alive at last contact had median follow-up of 24 (4-48) months. In sub-analysis of ELN22 intermediate/adverse risk pts (n=27), OS 79 (57-91)% was and RFS 54 (33-71)%. Pts in CR1 had higher OS/RFS compared with those in ≥CR2 (OS: 81 (56-92)% vs 57 (17-84)%; RFS: 59 (35-76)% vs 29 (4-61)%), respectively. To further assess the impact of haploNK on RFS, both correlative studies and comparative analyses to matched CIBMTR controls are underway.

Conclusions: Serial manufacturing and delivery of IL-21 expanded donor NK cells was successfully achieved for this national, multi-site, first-in-child HCT trial. Multi-dose NK cell immunotherapy combined with BuCy + PTCy haploHCT was feasible and safe, with low NRM and encouraging OS in this high-risk AML population. Our study supports further investigation of this relapse-prevention strategy to enhance durable disease control.

 

Hemalatha Geetharani Rangarajan I, MD: EDITAS - Other (including travel support); Medexus - Consultancy (Includes expert testimony); BEAM therapeutics - Consultancy (Includes expert testimony); Vertex Therapeutics - Consultancy (Includes expert testimony); NMDP Data Safety Monitoring Board CD33 CAR T (unpaid) - Consultancy (Includes expert testimony)